Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Zhi-Hong Liu, M.D.

Status: Terminated

Conditions: Polycystic Kidney

Treatments: Drug: Emodin; Drug: tripterygium wilfordii

Study type: Interventional

Funder types: Other

Identifiers

NCT00801268

NJCT-0802

Details and patient eligibility

About

Triptolide has been approve effective in animal model.

Full description

Randomized

Enrollment: 300 patients

Sex: All

Ages: 15 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically established ADPKD
• eGFR>30ml/min.
• Chinese nationality

Exclusion criteria

• Uncontrolled infections
• Non-ADPKD complications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)

---

300 participants in 2 patient groups

emodin

Active Comparator group

Treatment:

Drug: Emodin

Triptolide Woldifii

Experimental group

Description:

TW60mg/d

Treatment:

Drug: tripterygium wilfordii